Why cancer drug programs need human mass balance studies
Historically, drug programs for oncology and other rapidly fatal diseases didn’t include mass balance studies…
Danielle Pillsbury2024 年 9 月 23 日
Certara Launches Early Development Solution to Reduce Failure Rates in Early-Stage Drug Development
New solution offers early-stage developers a dedicated team of experts with combined experience in end-to-end…
Danielle Pillsbury2024 年 9 月 19 日
A close examination of BCRP’s role in lactation and methods for predicting drug distribution into milk
The article, authored by Caroline Sychterz, Hong Shen, Yueping Zhang, Michael Sinz, Amin Rostami-Hodjegan, Brian…
Danielle Pillsbury2024 年 9 月 18 日
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to…
Danielle Pillsbury2024 年 9 月 18 日
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Abstract Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually…
Renee Fisher2024 年 9 月 18 日
Towards a Platform Quantitative Systems Pharmacology (QSP) Model for Preclinical to Clinical Translation of Antibody Drug Conjugates (ADCs)
Abstract A next generation multiscale quantitative systems pharmacology (QSP) model for antibody drug conjugates (ADCs)…
Renee Fisher2024 年 9 月 18 日
A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers
Abstract T-cell engager (TCE) molecules activate the immune system and direct it to kill tumor…
Renee Fisher2024 年 9 月 18 日
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
Abstract Incorporating an early evaluation of dosing requirements is crucial for assessing the viability of…
Renee Fisher2024 年 9 月 18 日
